Igor Puzanov

September 24, 2015

Cancer therapies’ impact on heart, kidneys explored

Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys.

By Kathy Whitney
model of DNA double helix
August 20, 2015

New type of trial shows promise for several cancers

Anti-cancer drugs are typically tested on one type of cancer at a time. But an international consortium of cancer investigators, including Vanderbilt-Ingram Cancer Center (VICC) researchers, simultaneously tested an existing therapy in patients with several different forms of cancer that all exhibit the same tumor gene mutation.

By VUMC News and Communications
concept illustration of knee with pain radiating from it
August 6, 2015

New targeted therapy shows promise for rare joint tumor

Vanderbilt-Ingram Cancer Center (VICC) investigators and colleagues at several major medical centers have been testing a new targeted therapy that is showing promise for the treatment of a rare tumor that forms in and around joint cavities.

By VUMC News and Communications
October 16, 2014

Indiana couple hits the links to support melanoma research

A Vanderbilt-Ingram Cancer Center (VICC) melanoma patient is using his passion for golf to support melanoma research efforts at VICC.

By VUMC News and Communications
June 19, 2014

VICC researchers in spotlight at national cancer conference

New Vanderbilt research suggests patients with advanced melanoma — the most deadly form of skin cancer — could safely benefit from a combination of immunotherapy and targeted therapies aimed at specific gene mutations.

By VUMC News and Communications
October 25, 2012

Combined drug therapy may delay melanoma progression

Combination therapy with two drugs delayed the development of treatment resistance in patients with metastatic melanoma that expresses a specific mutation in the BRAF gene.

By VUMC News and Communications